Metabolic syndrome, classified by co-occurrence of three of the following symptoms: insulin resistance, dyslipidemia, elevated inflammation and CRP levels, and abdominal obesity and affecting approximately 37% of the US population and 49% of those over 60, increases the risk of cardiovascular morbidity and mortality1. The gene discussed is CRP; the disease is metabolic syndrome.